Barbara Ryan

Barbara Ryan founded Barbara Ryan Advisors, capital markets and communications advisory firm for the life sciences industry, in 2012 following a more than 30-year career on Wall Street as a sell-side research analyst and Managing Director covering the U.S. large-cap pharmaceutical industry, distributors, and PBMs. Ms. Ryan has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis, and corporate and communications strategy across the life sciences industry and has raised well over $1.5 billion in equity and convertible debt offerings. Ms. Ryan has been involved in several of the pharmaceutical industry's largest M&A transactions: Shire's defense against a hostile takeover attempt by Abbvie, Shire's takeover of Baxalta, Allergan's defense against Valeant, and Perrigo's defense again Mylan. Ms. Ryan served as an executive team member and on the disclosure committee of Radius Health from January 2014 to December 2017 and played a critical role in Radius' IPO and subsequent follow-on offerings which raised over $1 billion. Previously, Ms. Ryan was a Managing Director at Deutsche Bank/Alex Brown and head of the company's Pharmaceutical Research Team for 19 years. She began her research career covering the pharmaceutical industry at Bear Stearns in 1982. Ms. Ryan also covered drug wholesalers and PBMs and was the lead analyst on many high-profile IPOs, including Express Scripts, PSSI, Henry Schein, and Flamel Technologies. Ms. Ryan currently serves as a director on the board of MiNK Therapeutics as Audit Chair, INVO Biosciences, The Red Door Community NYC, a non-profit organization, and is on the Editorial Advisory Board of Pharmaceutical Executive Magazine, where she authors a monthly Finance Column, and is a member of the Editorial Advisory Board of the Prix Galien Foundation. Barbara is the founder of Fabulous Pharma Females, a non-profit whose mission is to advance women in the biopharma industry. Ms. Ryan has also led the development of women's leadership programs at several biotech companies.